Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Sign Up to like & getrecommendations! Published in 2020 at "Pharmaceutical Research"
DOI: 10.1007/s11095-020-02816-w
Abstract: Purpose ABP 710 has been developed as a biosimilar to infliximab reference product (RP). The objective of this study was to assess analytical similarity (structural and functional) between ABP 710 and infliximab RP licensed by… read more here.
Keywords: infliximab reference; similarity; infliximab; biosimilar infliximab ... See more keywords
Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Therapy"
DOI: 10.1111/dth.12846
Abstract: Real-life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of psoriasis is lacking. We retrospectively analysed patient records from 69 patients with moderate to severe psoriasis treated at the… read more here.
Keywords: effectiveness safety; biosimilar infliximab; safety; infliximab etanercept ... See more keywords
Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13239
Abstract: Based on extrapolation, biosimilar infliximab (IFX) was approved to treat inflammatory bowel disease (IBD). The first studies in adults have shown similar efficacy and safety in comparison with reference drug. The aim of this review… read more here.
Keywords: inflammatory bowel; biosimilar infliximab; bowel disease;
PTH-132 High rates of clinical response are maintained after switching from originator to biosimilar infliximab
Sign Up to like & getrecommendations! Published in 2019 at "Gut"
DOI: 10.1136/gutjnl-2019-bsgabstracts.191
Abstract: Introduction Biosimilar infliximab (BI) has been widely adopted in to clinical practice since launch in 2015. Switching patients with Inflammatory Bowel Disease (IBD) from originator infliximab (OI) to BI was endorsed by the BSG and… read more here.
Keywords: switch; biosimilar infliximab; clinical response; pre switch ... See more keywords
Experience with Biosimilar Infliximab (Remsima®) in Norway
Sign Up to like & getrecommendations! Published in 2017 at "Digestive Diseases"
DOI: 10.1159/000449088
Abstract: Background: The first monoclonal antibody biosimilar to be used in clinical practice is the tumour necrosis factor-alpha inhibitor Remsima® (CT-P13). The drug is approved for all indications as the originator infliximab (Remicade®) although clinical efficacy… read more here.
Keywords: biosimilar infliximab; treatment; experience biosimilar; ibd ... See more keywords